Charles (Chuck) Finn, PhD, Chief Executive Officer, Co-Founder
Dr. Finn is Chief Executive Officer at RRD International, LLC, and Chairman of ClearPath Development Company LLC, a subsidiary of RRD. Dr. Finn is one of the architects of RRD’s unique product development partnership model and is responsible for the overall direction of the company, creating development strategies, and managing the company’s core product development teams. Dr. Finn has more than 25 years of experience in the research, development, and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. Dr. Finn began his career as a Staff Fellow at FDA, Center for Biologics Evaluation and Research. He then entered industry, where he has held senior positions of increasing responsibility in regulatory affairs and product development. Dr. Finn worked for several companies prior to co-founding RRD in 2002, including Lederle-Praxis Biologicals, Miles Pharmaceuticals (Bayer), Genetics Institute, BRI International, and Quintiles. Dr. Finn received a PhD in Biology from Georgetown University and a BS in Zoology from the University of Maryland.
J. Scott Tarrant, President
Mr. Tarrant has over 25 years of technical sales, marketing, business development and operations experience with a range of early stage and publicly traded companies including the last 15 years in the biopharma industry. He served previously as RRD’s Chief Business Officer, responsible for leading and optimizing the company’s engagement model with its biopharma partners. Prior to joining RRD in 2010, Mr. Tarrant was EVP Global Sales and Marketing for UK based Xceleron Ltd, joining the company in 2004, and leading the formation of Xceleron’s US subsidiary in Maryland. Mr. Tarrant has also held executive and sales management positions at Gene Logic, TherImmune Research Corporation and Nalco Chemical Company. Mr. Tarrant is a former combat engineer officer in the United States Army. He received his B.S. in Biology from SUNY College of Environmental Science and Syracuse University and is a 2008 graduate of the International Executive Program in General Management at INSEAD, Fontainebleau, France and Singapore.
Ulrich Thienel, MD, PhD, Chief Development and Medical Officer
Dr. Thienel has extensive medical, product development and general management experience in early stage research through product commercialization. Prior to joining RRD, Dr. Thienel was Vice President of Asset Strategy at Takeda. During his tenure at Takeda he led multiple franchises including CNS, immunology, respiratory and inflammation. Previously, he held clinical development positions in immunology at Bristol-Myers Squibb and drug-device combination products at Johnson and Johnson. Dr. Thienel has broad experience in all four phases of clinical development including the filing of multiple NDAs and BLAs. Therapeutic areas of focus have included autoimmune and inflammatory diseases, GvHD and a broad range of neurological diseases. Dr. Thienel received his MD and PhD degrees from Justus-Liebig University in Giessen, Germany and completed his residency in internal medicine at Ludwigsburg Hospital in Heidelberg. After moving to the US in 1996, he continued his fellowship in rheumatology at Columbia University in New York. In 2015 Dr. Thienel completed his executive training in sales and marketing at the Kellogg Institute, Northwestern University.
Katherine Laessig, MD, Senior Vice President of Regulatory Affairs and Medical Safety
Dr. Laessig has over 16 years of regulatory experience at the US Food and Drug Administration (FDA) from 1999 through 2015. Most recently, she served as the Deputy Director of the Division of Anti-Infective Products (DAIP) for eight years and was responsible for review of antimicrobial drug and biologic products for the treatment as well as prevention of infectious diseases. Prior to joining DAIP, she held several positions of increasing responsibility in the Division of Antiviral Products. Her major area of expertise is antimicrobial product development. She remains active in clinical practice with a weekly clinic at the Whitman Walker Clinic in Washington, DC. Dr. Laessig began her career as an infectious disease specialist with Kaiser Permanente in the Washington, DC metropolitan area. She received her medical degree from the University of Maryland in Baltimore in 1992 and completed an internal medicine residency and infectious diseases fellowship, both at the George Washington University Medical Center in Washington, DC. She graduated from Cornell University in 1988 with a Bachelor of Arts in biology and a concentration in microbiology. She is board certified in infectious diseases and is a member of the Infectious Diseases Society of America and the American Society for Tropical Medicine and Hygiene.
Patrick (Pat) Frenchick, PhD, MBA, Senior Vice President of Scientific and Technical Operations
Dr. Frenchick has over 25 years of experience in the development of new therapeutic technologies, from discovery through initiation of clinical trials. Prior to joining RRD, he was Vice President for Clinical Operations at CytImmune Sciences, and before that Vice President of Development at Combinature BioPharma. He has worked in senior positions in the acquisition of technologies, strategic planning, and portfolio management in the US and in Europe. He has held the following academic positions: Adjunct Assistant Professor of Microbiology at the University of Saskatchewan, Research Faculty member at the Veterinary Infectious Disease Organization, and Postdoctoral Fellow in Virology at Baylor College of Medicine. Dr. Frenchick received a PhD in Immunology from the University of Minnesota and an MBA from Queen’s University (Kingston, ON, Canada). He is also a US Patent Agent.
Brian R. Gallagher, CMA – Senior Vice President & Chief Financial Officer
Mr. Gallagher is Senior Vice President & Chief Financial Officer at RRD International, LLC. Mr. Gallagher provides strategic, operational, and financial leadership to RRD. His primary responsibilities are planning, implementing, managing, and controlling all financial-related activities including the development of financial and operational strategies. Mr. Gallagher has over 20 years of finance experience in the biopharma industry with both multi-national corporations and commercial-stage public biotechnology companies. He has an extensive background in all areas of corporate controllership, including financial planning & analysis, cost control, management accounting, corporate administration, and systems implementation. He has supported all aspects of product development and commercialization, including the negotiation and execution of licensing and collaboration agreements with major pharma partners. Mr. Gallagher served previously as Vice President of Finance for Optimer Pharmaceuticals and, prior to that, as Senior Director of Finance and Corporate Controller for Adolor Corporation. He had a central role in the sale of both companies. Mr. Gallagher spent the first 10 years of his career with Therakos, Inc. (a Johnson & Johnson company) and Merck & Co., Inc. He received his BS in Finance from The Pennsylvania State University and is an active Certified Management Accountant (CMA).
Nicholas P. Zemo, Jr., Chief Business Officer
Mr. Zemo has over 20 years of sales, marketing, and operations, experience in the life sciences industry. He has grown businesses in various market segments and played instrumental roles on numerous acquisition and integration efforts. As Partner and Co-Founder of Catenate, he supported companies offering clinical, nonclinical, chemical manufacturing, and regulatory services in the development and execution of corporate and business development strategies, targeting biopharmaceutical and federal markets. As Principal and Founder of New Market Enterprises, he has built manufacturer-retailer partnerships across numerous retail channels. Prior to New Market Enterprises, Mr. Zemo was Vice President, Business Development, and a Co-Founder of Accelovance, a clinical Contract Research Organization with US and China operations. Mr. Zemo also held executive, sales management, and operations management positions at Gene Logic, TherImmune Research Corporation, and R.O.W. Sciences. Mr. Zemo received a BS in Animal Science from Virginia Tech.